- Home
- MDXH vs GNLX Comparison
MDXH vs GNLX Comparison
Compare MDXH & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDXH
- GNLX
- Stock Information
- Founded
- MDXH 2003
- GNLX 2001
- Country
- MDXH Belgium
- GNLX United States
- Employees
- MDXH N/A
- GNLX N/A
- Industry
- MDXH
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- MDXH
- GNLX Health Care
- Exchange
- MDXH Nasdaq
- GNLX Nasdaq
- Market Cap
- MDXH 118.3M
- GNLX 128.0M
- IPO Year
- MDXH 2021
- GNLX 2023
- Fundamental
- Price
- MDXH $2.66
- GNLX $3.15
- Analyst Decision
- MDXH Buy
- GNLX Strong Buy
- Analyst Count
- MDXH 1
- GNLX 5
- Target Price
- MDXH $6.00
- GNLX $16.20
- AVG Volume (30 Days)
- MDXH 98.6K
- GNLX 136.2K
- Earning Date
- MDXH 08-20-2025
- GNLX 08-07-2025
- Dividend Yield
- MDXH N/A
- GNLX N/A
- EPS Growth
- MDXH N/A
- GNLX N/A
- EPS
- MDXH N/A
- GNLX N/A
- Revenue
- MDXH $94,507,000.00
- GNLX N/A
- Revenue This Year
- MDXH $23.41
- GNLX N/A
- Revenue Next Year
- MDXH $18.50
- GNLX N/A
- P/E Ratio
- MDXH N/A
- GNLX N/A
- Revenue Growth
- MDXH 25.46
- GNLX N/A
- 52 Week Low
- MDXH $1.35
- GNLX $1.91
- 52 Week High
- MDXH $3.50
- GNLX $5.89
- Technical
- Relative Strength Index (RSI)
- MDXH 64.90
- GNLX 44.93
- Support Level
- MDXH $2.34
- GNLX $3.32
- Resistance Level
- MDXH $2.93
- GNLX $3.61
- Average True Range (ATR)
- MDXH 0.14
- GNLX 0.24
- MACD
- MDXH 0.02
- GNLX -0.04
- Stochastic Oscillator
- MDXH 54.24
- GNLX 1.79
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.